Drug Trial Radar · NCT00975195
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Feb 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,488
Actual
Start
Feb 2009
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled corticosteroid on top of two potent long-acting bronchodilators. The study also aims to identify the type of patients who are likely to benefit from inhaled corticosteroid maintenance therapy.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium inhalationDrug
salmeterol xinafoateDrug
fluticasone propionateDrug
placebo matched for fluticasone propionateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Moderate or Severe On-treatment COPD ExacerbationTime frame: During randomised treatment, up to 488 days
Locations
222 sites in 23 countries. Site status is shown where the registry gives one.
352.2046.61006 Boehringer Ingelheim Investigational Site
Concord, New South Wales, Australia
352.2046.61001 Boehringer Ingelheim Investigational Site
Glebe, New South Wales, Australia
352.2046.61002 Boehringer Ingelheim Investigational Site
Westmead, New South Wales, Australia
352.2046.61004 Boehringer Ingelheim Investigational Site
Daw Park, South Australia, Australia
352.2046.61003 Boehringer Ingelheim Investigational Site
Toorak Gardens, South Australia, Australia
352.2046.61005 Boehringer Ingelheim Investigational Site
Woodville, South Australia, Australia
352.2046.32002 Boehringer Ingelheim Investigational Site
Brussels, Belgium
352.2046.32016 Boehringer Ingelheim Investigational Site
Brussels, Belgium
352.2046.32015 Boehringer Ingelheim Investigational Site
Eupen, Belgium
352.2046.32017 Boehringer Ingelheim Investigational Site
Gilly, Belgium
352.2046.32014 Boehringer Ingelheim Investigational Site
Herentals, Belgium
352.2046.32006 Boehringer Ingelheim Investigational Site
Jambes, Belgium
352.2046.32008 Boehringer Ingelheim Investigational Site
Lebbeke, Belgium
352.2046.32001 Boehringer Ingelheim Investigational Site
Leuven, Belgium
352.2046.32004 Boehringer Ingelheim Investigational Site
Middelheim, Belgium
352.2046.32010 Boehringer Ingelheim Investigational Site
Montigny-le-Tilleul, Belgium
352.2046.32013 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
352.2046.55002 Boehringer Ingelheim Investigational Site
Goiânia, Brazil
352.2046.55005 Boehringer Ingelheim Investigational Site
Goiânia, Brazil
352.2046.55001 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
352.2046.55006 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
352.2046.55003 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
352.2046.35905 Boehringer Ingelheim Investigational Site
Burgas, Bulgaria
352.2046.35902 Boehringer Ingelheim Investigational Site
Rousse, Bulgaria
352.2046.35904 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
352.2046.35906 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
352.2046.35907 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
352.2046.35908 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
352.2046.35903 Boehringer Ingelheim Investigational Site
Stara Zagora, Bulgaria
352.2046.35909 Boehringer Ingelheim Investigational Site
Veliko Tarnovo, Bulgaria
352.2046.86002 Boehringer Ingelheim Investigational Site
Beijing, China
352.2046.86003 Boehringer Ingelheim Investigational Site
Beijing, China
352.2046.86006 Boehringer Ingelheim Investigational Site
Beijing, China
352.2046.86008 Boehringer Ingelheim Investigational Site
Chongqing, China
352.2046.86001 Boehringer Ingelheim Investigational Site
Guangzhou, China
352.2046.86004 Boehringer Ingelheim Investigational Site
Shanghai, China
352.2046.86005 Boehringer Ingelheim Investigational Site
Shanghai, China
352.2046.86007 Boehringer Ingelheim Investigational Site
Wuhan, China
352.2046.45001 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
352.2046.45003 Boehringer Ingelheim Investigational Site
København NV, Denmark
Showing 40 of 222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.